美股新聞 標題聯播 · 近 24 小時 337 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · VRDN近 30 天 0 則 · 第 1 / 1 頁
- Viridian Therapeutics to See 'Minimal' Revenue Growth in H2, RBC Capital Markets Says
- Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
- Graves Ophthalmopathy Market Expected to Witness Rapid Expansion at a CAGR of 9% During the Forecast Period (2026-2036), Driven by the Recent Approval of Viridian's LUMVOA and the Launch of Emerging Therapies | DelveInsight
- Lumvoa’s Unique Profile Leads to Optimism Around Viridian Therapeutics (VRDN)
- Viridian Therapeutics (VRDN) Rebounds Sharply, Is The Valuation Still Too Rich?
- Wedbush Sees Commercial Edge for Viridian (VRDN) After FDA Milestone
- Viridian Therapeutics' Lumvoa Could Start Generating More Meaningful Revenue in 2027, RBC Says
- Viridian may have edge over Amgen in eye drug showdown, analysts argue
- Comcast, Viridian Therapeutics jump premarket; Doximity slips
- Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
- Viridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350M
- Why Viridian Therapeutics (VRDN) Is Up 25.9% After Phase 3 Elegrobart Win And Fresh Fundraising
- Earnings Update: Viridian Therapeutics, Inc. (NASDAQ:VRDN) Just Reported And Analysts Are Boosting Their Estimates
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。